SonaCare Medical Exceeds Device Sales Goals

February 10, 2014

Strong global demand for the Sonablate® HIFU device results in six device sales in 2013

CHARLOTTE, N.C., Feb. 10, 2014 /PRNewswire/ — SonaCare Medical, a leader in minimally invasive high intensity focused ultrasound (HIFU) technology, sold six Sonablate® HIFU devices for the non-invasive treatment of prostate cancer in 2013.

The increasing interest in focal therapy and strong support for precision guided treatment technologies helped SonaCare Medical achieve device sales in four countries and four languages on three continents during the 2013 calendar year. Each of the devices sold contained the Sonablate® 500′s unique advanced technology, which includes high frequency imaging coupled with Tissue Change Monitoring (TCM) software, Neurovascular Bundle Detection (NVB) software and real-time imaging. Purchasers cited the new technology advancements, ease of use, new planning software, ability to fully customize every aspect of the treatment, superior safety features, high frequency imaging and transportability of the system as deciding factors that lead them to select purchasing the Sonablate device.

Alex Gonzalez, Vice President of Operations for SonaCare Medical said, “The increasing support for a focal ablation solution and a strong demand for a precision based technology with low toxicity profile capable of treating whole-gland and partial gland places the Sonablate at a significant advantage over any other HIFU device.” Mr. Gonzalez added, “We are quite pleased that we matched our prior unit sales record set last year and that the demand for devices in early 2014 is very strong, as we have already sold one device this year.”

Building on the success of 2013, SonaCare plans to showcase further advancements in its HIFU line of devices including both the Sonablate 500 and Sonatherm, a laparoscopic HIFU device, at the 29th Annual EAU Congress in April of 2014.

About SonaCare Medical

SonaCare Medical, a privately held, venture-backed healthcare company is a world leader in minimally invasive high intensity focused ultrasound (HIFU) technologies. SonaCare Medical is committed to developing technologies for urological indications that offer precise and innovative procedures that can control cancer and reduce potential quality of life altering side effects. SonaCare Medical, with its subsidiary Focus Surgery, Inc., designs and manufactures high intensity focused ultrasound (HIFU) medical devices, including the following: Sonablate® 450 which is investigational in the U.S. and being studied in a pivotal FDA clinical trial as a possible treatment for recurrent prostate cancer in patients treated previously with external beam radiation therapy; Sonablate® 500 which has CE Marking and is, or has been, approved for use to treat prostate cancer in more than 30 countries outside the U.S.; and Sonatherm® laparoscopic HIFU surgical ablation system which is 510(k) cleared in the U.S. The FDA has made no decision as to the safety or efficacy of Sonablate® 450 or 500. In the event Sonablate® 450 is approved by the FDA for use in the U.S., there is no assurance that instructions for use or the specifications of the device will be the same for treatment approved or authorized in other countries outside of the U.S.

SonaCare Medical was founded in 2004 and is headquartered in Charlotte, N.C. Additional information may be found at www.SonaCareMedical.com.

SOURCE SonaCare Medical

Source: PR Newswire

comments powered by Disqus